Organization
Regeneron Pharmaceuticals, Inc.
19 abstracts
Abstract
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.Org: Karmanos Cancer Institute, Ziekenhuis Netwerk Antwerpen Stuivenberg, Regeneron Pharmaceuticals, Inc.,
Abstract
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.Org: School of Biotechnology, Medical Oncology Department, CCRT/The Caroline Foundation, Galway University Hospital, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.Org: Memorial Sloan Kettering Cancer Center, Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, University of Cincinnati Cancer Center, START Midwest, Grand Rapids, MI,
Abstract
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).Org: Gustave Roussy Cancer Center, The Institute of Cancer Research/The Royal Marsden Hospital, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research, ISA Pharmaceuticals B.V., Regeneron Pharmaceuticals, Inc.,
Abstract
Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.Org: Regeneron Pharmaceuticals, Inc., IQVIA, Amsterdam, Netherlands,
Abstract
Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Org: Mayo Clinic, University Medical Center Hamburg-Eppendorf, Regeneron Pharmaceuticals, Inc., EVERSANA, Burlington, ON, Canada, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Inc., Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Karmanos Cancer Institute, University of Miami Health System,
Abstract
Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies.Org: Mayo Clinic Florida, Regeneron Pharmaceuticals, Inc., RTI Health Solutions,
Abstract
Incidence of any infections and SARS-CoV-2 infections in patients receiving treatment for follicular lymphoma and diffuse large B-cell lymphoma: Real-world evidence from a large US national claims database.Org: Regeneron Pharmaceuticals, Inc.,
Abstract
Machine learning-based multimodal prediction of prognosis in patients with resected intrahepatic cholangiocarcinoma.Org: Owkin France, Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals, Inc.,
Abstract
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.Org: Johns Hopkins Kimmel Cancer Center, Regeneron Pharmaceuticals, Inc., Department of Nuclear Medicine Zürich, University Hospital of Zürich, Department of Medical Oncology, Başkent University, High Technology Medical Centre, University Clinic,
Abstract
Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.Org: City of Hope National Medical Center, City of Hope Medical Group, City of Hope Cancer Center, City of Hope Comprehensive Cancer Center, City of Hope National Comprehensive Cancer Center,
Abstract
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).Org: Thoracic Head & Neck Medical Oncology, MD Anderson Cancer Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, Başkent University, Istinye University Faculty of Medicine,
Abstract
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.Org: University of Tennessee Medical Center at Knoxville, Orlando Health Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, St. John's Cancer Institute, Santa Monica, CA,
Abstract
CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting.Org: Charleston Oncology, The Melanoma And Skin Cancer Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Department of Hematology and Oncology, Miami Cancer Institute/Baptist Health South Florida, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, Spectrum Medical Group, Columbia University Irving Medical Center, New York, NY, USA, Columbia University Medical Center,
Abstract
BENEFIT OF SARILUMAB WITH CSDMARDS ON PATIENT PRODUCTIVITY IN WORK, HOUSEHOLD WORK AND FAMILY, SOCIAL, LEISURE ACTIVITIES IN TNF-IR RA PATIENTS Org: Stanford University School of Medicine, Sanofi, Regeneron Pharmaceuticals, Inc., Discipline of Rheumatology, Rio de Janeiro State University, Altoona Center for Clinical Research, Duncansville, United States of America,